Prevention and treatment of diuretic resistance in acute heart failure: when to use which combination of diuretics?

Affiliations

¹ Kauffman Center for Heart Failure Treatment and Recovery, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
² Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA.
³ University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.

Editorial

Pieter Martens et al. Eur Heart J. 2023.

. 2023 Aug 14;44(31):2978-2981.

doi: 10.1093/eurheartj/ehad463.

¹ Kauffman Center for Heart Failure Treatment and Recovery, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
² Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA.
³ University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.

No abstract available

Comment on

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics.
Yeoh SE, Osmanska J, Petrie MC, Brooksbank KJM, Clark AL, Docherty KF, Foley PWX, Guha K, Halliday CA, Jhund PS, Kalra PR, McKinley G, Lang NN, Lee MMY, McConnachie A, McDermott JJ, Platz E, Sartipy P, Seed A, Stanley B, Weir RAP, Welsh P, McMurray JJV, Campbell RT. Yeoh SE, et al. Eur Heart J. 2023 Aug 14;44(31):2966-2977. doi: 10.1093/eurheartj/ehad341. Eur Heart J. 2023. PMID: 37210742 Free PMC article. Clinical Trial.